AP NEWS

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018 Featuring Daewoong Pharmaceutical, RaQualia Pharma & Zeria Pharmaceutical - ResearchAndMarkets.com

September 28, 2018

DUBLIN--(BUSINESS WIRE)--Sep 28, 2018--The “Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Functional (Non Ulcer) Dyspepsia (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline guide also reviews key players involved in therapeutic development for Functional (Non Ulcer) Dyspepsia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Report Coverage Functional (Non Ulcer) Dyspepsia - Overview Functional (Non Ulcer) Dyspepsia - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Functional (Non Ulcer) Dyspepsia - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Functional (Non Ulcer) Dyspepsia - Companies Involved in Therapeutics Development Daewoong Pharmaceutical Co Ltd RaQualia Pharma Inc Zeria Pharmaceutical Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/z68fsr/functional_non?w=4.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180928005659/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Gastrointestinal Drugs

KEYWORD:

INDUSTRY KEYWORD: EDUCATION UNIVERSITY HEALTH CLINICAL TRIALS PHARMACEUTICAL MANAGED CARE

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/28/2018 05:59 PM/DISC: 09/28/2018 05:59 PM

http://www.businesswire.com/news/home/20180928005659/en

AP RADIO
Update hourly